H. Dubbink

发表

The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study

M. J. van den Bent, O. Schijns, M. Smits, 2018, Neuro-oncology.

The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis

M. J. van den Bent, W. Dinjens, A. Vincent, 2017, Neuro-oncology.

Predicting the 1p/19q Codeletion Status of Presumed Low-Grade Glioma with an Externally Validated Machine Learning Algorithm

S. Klein, M. J. van den Bent, W. Niessen, 2019, Clinical Cancer Research.

Federated learning enables big data for rare cancer boundary detection

Bjoern H Menze, Amber L. Simpson, James F. Gimpel, 2022, Nature Communications.

Compartmentalization of androgen receptor protein–protein interactions in living cells

Adriaan B. Houtsmuller, Pernette J. Verschure, Martin E. van Royen, 2007, The Journal of cell biology.

Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics

Johan M. Kros, Pim J. French, Hendrikus J. Dubbink, 2018, Acta Neuropathologica Communications.

Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification

W. Dinjens, M. Bent, A. Vincent, 2017, Acta Neuropathologica.

WHO 2016 subtyping and automated segmentation of glioma using multi-task deep learning pdf

Wiro J. Niessen, Marion Smits, Stefan Klein, 2020, ArXiv.

Yield of routine molecular analyses in colorectal cancer patients ≤70 years to detect underlying Lynch syndrome

E. Kuipers, E. Steyerberg, A. V. D. van den Ouweland, 2012, The Journal of pathology.

Segregation of non‐p.R132H mutations in IDH1 in distinct molecular subtypes of glioma

C. Hoogenraad, M. J. van den Bent, W. Dinjens, 2010, Human mutation.

Cost-effectiveness of routine screening for Lynch syndrome in endometrial cancer patients up to 70years of age.

E. Steyerberg, A. V. D. van den Ouweland, A. Wagner, 2016, Gynecologic oncology.

Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤ 70 years.

E. Kuipers, E. Steyerberg, A. V. D. van den Ouweland, 2012, Gynecologic oncology.

Human prostate-specific transglutaminase: a new prostatic marker with a unique distribution pattern.

T. H. van der Kwast, F. Schröder, J. Romijn, 1999, Laboratory investigation; a journal of technical methods and pathology.

Novel EGFR V834L Germline Mutation Associated With Familial Lung Adenocarcinoma

J. Aerts, A. Wagner, W. Dinjens, 2018, JCO precision oncology.

Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma

M. J. van den Bent, W. Dinjens, A. Vincent, 2018, Journal of Neuro-Oncology.

Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects

A. Sieuwerts, M. Smid, J. Martens, 2018, Clinical Cancer Research.

Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA

S. Sleijfer, K. Nasserinejad, W. Dinjens, 2020, Molecular oncology.

Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation

S. Klein, M. J. van den Bent, G. Lycklama, 2020, Frontiers in Oncology.

Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation.

A. Dingemans, H. Dubbink, M. Paats, 2021, JCO precision oncology.

Differences in spatial distribution between WHO 2016 low-grade glioma molecular subgroups

S. Klein, M. J. van den Bent, W. Dinjens, 2019, Neuro-oncology advances.

OS10.1 Survival analysis of IDH wildtype astrocytomas with molecular features of glioblastoma, WHO grade IV

M. J. van den Bent, M. Taphoorn, M. Smits, 2019, Neuro-Oncology.

Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers

D. Nieboer, E. Steyerberg, A. Wagner, 2017, Familial Cancer.

Response to: An immunohistochemical approach to detect oncogenic CTNNB1 mutations in primary neoplastic tissues

R. Smits, M. Lavrijsen, H. Dubbink, 2019, Laboratory Investigation.

Cost-effectiveness of routine screening for Lynch syndrome in colorectal cancer patients up to 70 years of age

E. Kuipers, E. Steyerberg, A. V. D. van den Ouweland, 2016, Genetics in Medicine.

Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer

J. Aerts, W. Dinjens, C. H. van der Leest, 2020, Cancers.

Plasma Cell-Free DNA Testing of Patients With EGFR Mutant Non-Small-Cell Lung Cancer: Droplet Digital PCR Versus Next-Generation Sequencing Compared With Tissue-Based Results.

J. Aerts, W. Dinjens, E. de Jonge, 2019, JCO precision oncology.

Guidelines on Genetic Evaluation and Management of Lynch Syndrome

A. Wagner, W. Dinjens, H. Dubbink, 2015, The American Journal of Gastroenterology.

Functional Analysis of Novel Androgen Receptor Mutations in a Unique Cohort of Indonesian Patients with a Disorder of Sex Development

A. Houtsmuller, J. Trapman, M. V. van Royen, 2009, Sexual Development.

Prognostic value of TERT promoter mutations in conjunctival melanomas in addition to clinicopathological features

N. Naus, R. Verdijk, H. Dubbink, 2020, British Journal of Ophthalmology.

Guidelines on genetic evaluation and management of Lynch syndrome.

A. Wagner, W. Dinjens, H. Dubbink, 2015, Gastrointestinal endoscopy.

TP53 Mutation Analysis of Malignant Peripheral Nerve Sheath Tumors

W. Hop, W. Dinjens, M. D. den Bakker, 2010, Journal of neuropathology and experimental neurology.

Expression of prostatic factors measured by reverse transcription polymerase chain reaction in human papillomavirus type 18 deoxyribonucleic acid immortalized prostate cell lines.

P. Weijerman, F. Schröder, D. Peehl, 1998, Urology.

Routine Molecular Analysis for Lynch Syndrome Among Adenomas or Colorectal Cancer Within a National Screening Program.

A. Wagner, W. Dinjens, R. Hofstra, 2018, Gastroenterology.

Combined mutation and copy-number variation detection by targeted next-generation sequencing in uveal melanoma

A. Klein, R. Verdijk, S. Coupland, 2018, Modern Pathology.

Combined germline pathogenic variants in FLCN and TP53 are associated with early onset renal cell carcinoma and brain tumors

E. Bongers, R. Wolthuis, H. Meijers-Heijboer, 2022, Molecular genetics & genomic medicine.

Recommendations for the clinical interpretation and reporting of copy number gains using gene panel NGS analysis in routine diagnostics

B. Tops, E. Schuuring, P. Nederlof, 2019, Virchows Archiv.

An Sp1 binding site is essential for basal activity of the human prostate-specific transglutaminase gene (TGM4) promoter.

J. Romijn, H. Dubbink, K. Cleutjens, 1999, Gene.

TERT promoter mutations and BRAF mutations are rare in sporadic, and TERT promoter mutations are absent in NF1-related malignant peripheral nerve sheath tumors

E. Zwarthoff, E. Post, R. Verdijk, 2014, Journal of Neuro-Oncology.

Federated learning enables big data for rare cancer boundary detection

Bjoern H Menze, Amber L. Simpson, James F. Gimpel, 2022, Nature Communications.

Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant therapy.

A. Dingemans, J. H. von der Thüsen, H. Dubbink, 2022, European journal of cancer.

Systematic Structure-Function Analysis of Androgen Receptor Leu701 Mutants Explains the Properties of the Prostate Cancer Mutant L701H*

Guido Jenster, Hendrikus J Dubbink, Scott J Lusher, 2009, The Journal of Biological Chemistry.

Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?

M. J. van den Bent, P. French, H. Dubbink, 2011, The Lancet. Oncology.

Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions.

E. Zwarthoff, E. Post, N. Naus, 2014, Investigative ophthalmology & visual science.

The human prostate-specific transglutaminase gene (TGM4): genomic organization, tissue-specific expression, and promoter characterization.

N. Verkaik, J. Trapman, J. Romijn, 1998, Genomics.

Prevalence of c-KIT Mutations in Gonadoblastoma and Dysgerminomas of Patients with Disorders of Sex Development (DSD) and Ovarian Dysgerminomas

W. Dinjens, L. Looijenga, H. Stoop, 2012, PloS one.

Androgen receptor coregulators: Recruitment via the coactivator binding groove

G. Jenster, J. Trapman, H. Dubbink, 2012, Molecular and Cellular Endocrinology.

Inhibition of androgen receptor functions by gelsolin FxxFF peptide delivered by transfection, cell‐penetrating peptides, and lentiviral infection

G. Jenster, J. Trapman, H. Dubbink, 2011, The Prostate.

Functional screening of FxxLF-like peptide motifs identifies SMARCD1/BAF60a as an androgen receptor cofactor that modulates TMPRSS2 expression.

G. Jenster, J. Trapman, H. Dubbink, 2009, Molecular endocrinology.

Interlaboratory comparison of IDH mutation detection

K. Aldape, M. Sanson, M. Bent, 2013, Journal of Neuro-Oncology.

TP53 mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2

S. Sleijfer, M. Lamfers, S. Leenstra, 2016, Oncotarget.

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide

M. J. van den Bent, W. Dinjens, T. Postma, 2009, Neurology.

Direct Ex Vivo Observation of Homologous Recombination Defect Reversal After DNA-Damaging Chemotherapy in Patients With Metastatic Breast Cancer.

A. Jager, W. Dinjens, C. V. van Deurzen, 2019, JCO precision oncology.

Next generation diagnostic molecular pathology: Critical appraisal of quality assurance in Europe

B. Tops, W. Dinjens, Z. Deans, 2014, Molecular oncology.

SNPitty: An Intuitive Web Application for Interactive B-Allele Frequency and Copy Number Visualization of Next-Generation Sequencing Data.

Guido Jenster, Job van Riet, Niels M G Krol, 2018, The Journal of molecular diagnostics : JMD.

Survival of diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.

M. J. van den Bent, M. Taphoorn, A. Vincent, 2019, Neuro-oncology.

Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics

M. J. van den Bent, W. Dinjens, P. French, 2018, Acta neuropathologica communications.

Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.

Pieter Wesseling, Peggy N Atmodimedjo, Hendrikus J Dubbink, 2016, Neuro-oncology.

Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer.

J. L. Costa, F. Rojo, R. Yacobi, 2018, The Journal of molecular diagnostics : JMD.

Combined molecular subtyping, grading, and segmentation of glioma using multi-task deep learning

M. J. van den Bent, W. Niessen, P. C. de Witt Hamer, 2022, Neuro-oncology.

IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

Pieter Wesseling, Hendrikus J Dubbink, Winand N M Dinjens, 2010, Clinical Cancer Research.

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.

K. Aldape, W. Mason, M. J. van den Bent, 2021, The Lancet. Oncology.

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

D. Brachman, R. Stupp, W. Mason, 2017, The Lancet.

MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

M. J. van den Bent, M. Taphoorn, A. Brandes, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Somatic aberrations of mismatch repair genes as a cause of microsatellite‐unstable cancers

E. Kuipers, E. Steyerberg, A. V. D. van den Ouweland, 2014, The Journal of pathology.

Functional analysis of MSH2 unclassified variants found in suspected Lynch syndrome patients reveals pathogenicity due to attenuated mismatch repair

S. Verhoef, A. V. D. van den Ouweland, A. Wagner, 2014, Journal of Medical Genetics.

Unexplained mismatch repair deficiency: Case closed

H. Dubbink, T. V. van Ham, M. Spaander, 2022, HGG advances.

Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC

E. Smit, P. Postmus, T. van Wezel, 2021, JTO Clinical and Research Reports.

MET immunochemistry: a reliable screening tool for MET exon 14 skipping mutations in non-small cell lung cancer?

J. H. von der Thüsen, H. Dubbink, M. Pruis, 2020, Annals of translational medicine.

The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder

W. Dinjens, E. Zwarthoff, H. V. D. van de Werken, 2020, International journal of cancer.

Androgen receptor ligand-binding domain interaction and nuclear receptor specificity of FXXLF and LXXLL motifs as determined by L/F swapping.

G. Jenster, A. Pike, J. Trapman, 2006, Molecular endocrinology.

A review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory

E. Kuipers, E. Steyerberg, A. Wagner, 2009, Journal of cellular and molecular medicine.

Amino acids 3-13 and amino acids in and flanking the 23FxxLF27 motif modulate the interaction between the N-terminal and ligand-binding domain of the androgen receptor.

J. Trapman, A. Brinkmann, H. Dubbink, 2002, European journal of biochemistry.

Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma

K. Aldape, H. Noushmehr, W. Mason, 2021, Neuro-oncology.

Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations

K. Aldape, W. Mason, M. J. van den Bent, 2021, Acta Neuropathologica.

DNA methylation and survival differences associated with the type of IDH mutation in 1p/19q non-codeleted astrocytomas

K. Aldape, W. Mason, M. J. van den Bent, 2020, bioRxiv.

The role of cofactors in sex steroid action.

J. Trapman, H. Dubbink, 2007, Best practice & research. Clinical endocrinology & metabolism.

Diagnostic Detection of Allelic Losses and Imbalances by Next-Generation Sequencing: 1p/19q Co-Deletion Analysis of Gliomas.

M. J. van den Bent, P. Riegman, W. Dinjens, 2016, The Journal of molecular diagnostics : JMD.

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

R. Vernhout, M. J. van den Bent, M. Taphoorn, 2014, The Lancet. Oncology.

Unexpected moves: a conformational change in MutSα enables high-affinity DNA mismatch binding

N. de Wind, T. Sixma, Hellen Houlleberghs, 2023, Nucleic acids research.

Clinical validation of Whole Genome Sequencing for cancer diagnostics.

A. Hoischen, E. Cuppen, B. Ylstra, 2021, The Journal of molecular diagnostics : JMD.

Clinical validation of Whole Genome Sequencing for routine cancer diagnostics

Stef van Lieshout, A. Hoischen, E. Cuppen, 2020, medRxiv.

INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

M. J. van den Bent, M. Weller, T. Gorlia, 2019, Neuro-oncology.

Data belonging to Predicting the 1p/19q co-deletion status of presumed low grade glioma with an externally validated machine learning algorithm

S. Klein, W. Niessen, R. Tewarie, 2020 .

A novel tissue‐based ß‐catenin gene and immunohistochemical analysis to exclude familial adenomatous polyposis among children with hepatoblastoma tumors

A. Wagner, R. Smits, M. V. van Noesel, 2018, Pediatric blood & cancer.

Correlation of Gene Mutation Status with Copy Number Profile in Uveal Melanoma.

B. Beverloo, N. Naus, A. de Klein, 2017, Ophthalmology.

Metastatic Disease in Polyploid Uveal Melanoma Patients Is Associated With BAP1 Mutations.

B. Beverloo, N. Naus, A. de Klein, 2016, Investigative ophthalmology & visual science.

The Association Between the Extent of Glioblastoma Resection and Survival in Light of MGMT Promoter Methylation in 326 Patients With Newly Diagnosed IDH-Wildtype Glioblastoma

M. J. van den Bent, A. Vincent, M. Smits, 2020, Frontiers in Oncology.

ALK in Mesothelioma: To FISH or Not to FISH?

J. H. von der Thüsen, H. Dubbink, R. Cornelissen, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Granular dot-like staining with MLH1 immunohistochemistry is a clone-dependent artefact.

W. Dinjens, K. Biermann, P. Ewing-Graham, 2019, Pathology, research and practice.

Novel FXXFF and FXXMF Motifs in Androgen Receptor Cofactors Mediate High Affinity and Specific Interactions with the Ligand-binding Domain*

G. Jenster, A. Houtsmuller, A. Pike, 2006, Journal of Biological Chemistry.

Identification of Familial Adenomatous Polyposis carriers among children with desmoid tumours.

A. V. D. van den Ouweland, A. Wagner, W. Dinjens, 2012, European journal of cancer.

In‐depth molecular analysis of combined and co‐primary pulmonary large cell neuroendocrine carcinoma and adenocarcinoma

A. Dingemans, W. Timens, R. V. van Suylen, 2021, International journal of cancer.

Molecular Genetics of Conjunctival Melanoma and Prognostic Value of TERT Promoter Mutation Analysis

N. Naus, A. de Klein, R. Verdijk, 2021, International journal of molecular sciences.

First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response.

M. J. van den Bent, W. Dinjens, T. Postma, 2011, Neuro-oncology.

LABORATORY INVESTIGATION- HUMAN/ANIMAL TISSUE

M. J. van den Bent, W. Dinjens, J. Kros, 2022 .

The Erasmus Glioma Database (EGD): Structural MRI scans, WHO 2016 subtypes, and segmentations of 774 patients with glioma

S. Klein, M. J. van den Bent, A. Vincent, 2021, Data in brief.

Donor‐transmitted metastasis of colorectal carcinoma in a transplanted liver

W. Dinjens, H. Metselaar, J. Verheij, 2012, Transplant international : official journal of the European Society for Organ Transplantation.

Oligonucleotide-directed mutagenesis screen to identify pathogenic Lynch syndrome-associated MSH2 DNA mismatch repair gene variants

S. Verhoef, R. Hofstra, Hellen Houlleberghs, 2016, Proceedings of the National Academy of Sciences.

Distinct recognition modes of FXXLF and LXXLL motifs by the androgen receptor.

Chandra S Verma, Hendrikus J Dubbink, Jan Trapman, 2004, Molecular endocrinology.

Tissue specific and androgen-regulated expression of human prostate-specific transglutaminase.

N. Verkaik, J. Romijn, H. Dubbink, 1996, The Biochemical journal.

Impact of panel design and cut-off on tumour mutational burden assessment in metastatic solid tumour samples

S. Sleijfer, E. Cuppen, P. Roepman, 2020, British Journal of Cancer.

Tobacco smoking related mutational signatures in classifying smoking associated and non-smoking associated non-small cell lung cancer.

E. Smit, J. Aerts, A. Dingemans, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers

D. Nieboer, E. Steyerberg, A. Wagner, 2017, Familial Cancer.

The androgen receptor ligand-binding domain stabilizes DNA binding in living cells.

Hendrikus J Dubbink, Jan Trapman, Bart Geverts, 2004, Journal of structural biology.

Gynecological Surveillance and Surgery Outcomes in Dutch Lynch Syndrome Carriers

A. Wagner, W. Dinjens, H. V. van Doorn, 2021, Cancers.

Impact of panel design and cut-off on tumour mutational burden assessment in metastatic solid tumour samples

S. Sleijfer, E. Cuppen, W. Dinjens, 2020, British Journal of Cancer.

A novel mutation F826L in the human androgen receptor in partial androgen insensitivity syndrome; increased NH2-/COOH-terminal domain interaction and TIF2 co-activation

J. Trapman, J. Grootegoed, A. Brinkmann, 2008, Molecular and Cellular Endocrinology.

Mitochondrial D310 mutation as clonal marker for solid tumors

W. Dinjens, H. Dubbink, P. Atmodimedjo, 2015, Virchows Archiv.